Deutsche Bank’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-34,956
| Closed | -$169K | – | 4613 |
|
|
2020
Q1 | $169K | Buy |
34,956
+18,163
| +108% | +$118K | ﹤0.01% | 3026 |
|
|
2019
Q4 | $177K | Buy |
16,793
+3,815
| +29% | +$37.9K | ﹤0.01% | 3304 |
|
|
2019
Q3 | $134K | Sell |
12,978
-987
| -7% | -$12.9K | ﹤0.01% | 3400 |
|
|
2019
Q2 | $212K | Buy |
13,965
+2,092
| +18% | +$30.3K | ﹤0.01% | 3784 |
|
|
2019
Q1 | $152K | Sell |
11,873
-4,424
| -27% | -$50K | ﹤0.01% | 4147 |
|
|
2018
Q4 | $154K | Sell |
16,297
-71,419
| -81% | -$926K | ﹤0.01% | 4013 |
|
|
2018
Q3 | $1.46M | Sell |
87,716
-3,849
| -4% | -$61.7K | ﹤0.01% | 3054 |
|
|
2018
Q2 | $1.47M | Buy |
91,565
+17,586
| +24% | +$314K | ﹤0.01% | 3155 |
|
|
2018
Q1 | $1.13M | Buy |
73,979
+23,630
| +47% | +$368K | ﹤0.01% | 3233 |
|
|
2017
Q4 | $784K | Sell |
50,349
-143,797
| -74% | -$1.92M | ﹤0.01% | 3366 |
|
|
2017
Q3 | $2.15M | Sell |
194,146
-4,464
| -2% | -$42K | ﹤0.01% | 2490 |
|
|
2017
Q2 | $1.83M | Buy |
198,610
+78,560
| +65% | +$655K | ﹤0.01% | 2620 |
|
|
2017
Q1 | $1.02M | Sell |
120,050
-51,798
| -30% | -$472K | ﹤0.01% | 2645 |
|
|
2016
Q4 | $1.84M | Buy |
171,848
+33,100
| +24% | +$400K | ﹤0.01% | 2315 |
|
|
2016
Q3 | $1.5M | Buy |
138,748
+21,987
| +19% | +$179K | ﹤0.01% | 2543 |
|
|
2016
Q2 | $789K | Buy |
116,761
+5,890
| +5% | +$37.2K | ﹤0.01% | 3047 |
|
|
2016
Q1 | $515K | Buy |
110,871
+68,484
| +162% | +$334K | ﹤0.01% | 3196 |
|
|
2015
Q4 | $265K | Buy |
42,387
+38,045
| +876% | +$309K | ﹤0.01% | 3578 |
|
|
2015
Q3 | $37K | Sell |
4,342
-2,140
| -33% | -$22.5K | ﹤0.01% | 4568 |
|
|
2015
Q2 | $74K | Buy |
6,482
+4,658
| +255% | +$64.7K | ﹤0.01% | 4395 |
|
|
2015
Q1 | $26K | Sell |
1,824
-3,983
| -69% | -$61K | ﹤0.01% | 4598 |
|
|
2014
Q4 | $98K | Buy |
5,807
+3,712
| +177% | +$53.5K | ﹤0.01% | 4733 |
|
|
2014
Q3 | $25K | Buy |
2,095
+1,832
| +697% | +$22.5K | ﹤0.01% | 5130 |
|
|
2014
Q2 | $2K | Sell |
263
-6,603
| -96% | -$101K | ﹤0.01% | 5737 |
|
|
2014
Q1 | $139K | Buy |
6,866
+1,640
| +31% | +$39.8K | ﹤0.01% | 4088 |
|
|
2013
Q4 | $102K | Sell |
5,226
-6,909
| -57% | -$184K | ﹤0.01% | 4047 |
|
|
2013
Q3 | $549K | Buy |
12,135
+6,579
| +118% | +$215K | ﹤0.01% | 3418 |
|
|
2013
Q2 | $132K | Buy |
+5,556
| New | +$88.5K | ﹤0.01% | 4067 |
|
Deutsche Bank's STML Position: Q2 2020 in Review
Deutsche Bank sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 34,956 shares — an estimated $169K sold.
Deutsche Bank first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $2.15M in Q3 2017. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Deutsche Bank reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Deutsche Bank sold 34,956 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $169K.
- Deutsche Bank first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Deutsche Bank's Stemline Therapeutics, Inc. position peaked at $2.15M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Deutsche Bank's 13F filing for Q2 2020, filed 13 Aug 2020.